3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
3
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gynecologic
3
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
1215
Neoplasms
1024
Carcinoma, Non-Small-Cell Lung
747
Prostatic Neoplasms
687
Colorectal Neoplasms
590
Lung Neoplasms
572
Pancreatic Neoplasms
394
Leukemia, Myeloid, Acute
394
Neoplasm Metastasis
387
Ovarian Neoplasms
370
Multiple Myeloma
369
Stomach Neoplasms
316
Carcinoma, Hepatocellular
301
Melanoma
281
Brain Neoplasms
277
Recurrence
273
Squamous Cell Carcinoma of Head and Neck
267
Head and Neck Neoplasms
237
Endometrial Neoplasms
234
Glioblastoma
233
Triple Negative Breast Neoplasms
228
Uterine Cervical Neoplasms
221
Precursor Cell Lymphoblastic Leukemia-Lymphoma
221
Lymphoma
221
Sarcoma
201
Hematologic Neoplasms
199
Urinary Bladder Neoplasms
196
Esophageal Neoplasms
190
Carcinoma, Renal Cell
187
Lymphoma, Non-Hodgkin
175
Interventions
artesunic acid
1
artenimol
1
artemisinin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Vulvar Diseases
×
1 year
×
Clear all
NCT06495554
2026-04-29
DaVulvaRec
University of Aarhus
Phase NA
Recruiting
1,295 enrolled
NCT06075264
2025-08-14
ART-VIN IIB
Frantz Viral Therapeutics, LLC
Phase 2
Recruiting
27 enrolled
NCT05592626
2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
365 enrolled